Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $290 | $440 | $152 | $325 | $227 |
| Gross Profit | $278 | $429 | $138 | $315 | $215 |
| Operating Income | -$172 | -$30 | -$410 | -$354 | -$475 |
| Net Income | -$451 | -$29 | -$270 | -$366 | -$454 |
Over the five-year period, Ionis Pharmaceuticals’ financial performance has been notably volatile. In 2020, the company generated approximately $290.3 million in revenue and achieved a gross profit of around $278.3 million, but it struggled with significant operating and net losses (–$172.1 million and –$451.3 million, respectively). In 2021, revenue increased by roughly 51%, reaching $440.0 million, and gross profit expanded to $429.2 million. Notably, operating income improved dramatically, with losses narrowing to –$30.2 million, and net income turned much less negative at –$28.6 million. This turnaround in 2021 might be attributed to operational efficiencies or a favorable shift in product mix within the competitive biopharmaceutical sector. However, the subsequent years reveal marked swings: in 2022, revenue dropped by nearly 65% to $151.9 million, accompanied by a commensurate contraction in gross profit to $137.8 million and a steep deterioration in operating income (–$410.2 million). In 2023, revenue rebounded to $324.5 million and gross profit followed suit, rising to $315.4 million, yet operating losses remained sizable at –$353.7 million. The pattern continued into 2024 with revenue dipping to $226.6 million and gross profit to $215.4 million, while operating results further deteriorated (–$475.1 million) and net income hovered at significant losses (–$453.9 million). Overall, while there was a positive shift in 2021, the recurring large swings—particularly in revenue and operating metrics—suggest persistent challenges in achieving stable profitability, raising concerns about the company’s medium-term financial sustainability in a highly competitive, innovation-driven industry.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.